Generic Revlimid (Lenalid 25 mg) – Lenalidomide Capsules | Dubai, UAE (2026)
Product Name
Brand Name: Lenalid 25 mg Capsules
Generic Name: Lenalidomide 25 mg
Reference Medicine: Revlimid® (Generic Equivalent)
Therapeutic Class: Immunomodulatory Agent (IMiD)
Dosage Form: Hard Gelatin Capsules
Product Details
Lenalid 25 mg contains Lenalidomide 25 mg, an immunomodulatory medicine widely used in the treatment of Multiple Myeloma and selected blood disorders. It helps slow cancer cell growth, enhances the body's immune response against malignant plasma cells, and reduces the formation of new blood vessels that support tumor growth.
Lenalidomide is commonly prescribed in combination with Dexamethasone, Bortezomib, Daratumumab, or other anti-myeloma therapies depending on the stage of disease and patient condition. It is a prescription-only medicine that requires close supervision by an oncologist or haematologist. International treatment guidelines continue to recommend lenalidomide-containing regimens for many patients with multiple myeloma.
Product Specification
| Brand Name | Lenalid 25 mg |
| Generic Name | Lenalidomide |
| Strength | 25 mg |
| Dosage Form | Hard Capsule |
| Route of Administration | Oral |
| Therapeutic Category | Immunomodulatory Agent (IMiD) |
| Indications | Multiple Myeloma, Myelodysplastic Syndrome (selected patients), Mantle Cell Lymphoma, Follicular Lymphoma (as indicated) |
| Prescription Status | Prescription Only Medicine |
| Storage | Store below 30°C in a dry place away from sunlight |
| Packaging | Blister Pack |
| Manufacturer | GMP Certified Pharmaceutical Manufacturer |
Key Features
- Contains Lenalidomide 25 mg
- Generic equivalent of Revlimid®
- Used for the treatment of Multiple Myeloma
- Oral capsule for convenient administration
- Helps inhibit cancer cell growth
- Enhances immune system activity against abnormal plasma cells
- Commonly combined with Dexamethasone and other anti-cancer medicines
- Manufactured in WHO-GMP compliant facilities
- Quality-tested for purity, safety, and efficacy
- Available for international pharmaceutical export where legally permitted
Industry Update
Multiple myeloma treatment in the UAE continues to align with international oncology standards, with specialist cancer centres increasingly adopting combination therapies that include Lenalidomide alongside targeted agents such as Daratumumab, Bortezomib, and Dexamethasone for eligible patients. Current international oncology guidelines continue to support lenalidomide-based regimens across multiple treatment settings.
In 2026, treatment decisions in Dubai remain individualized based on disease stage, transplant eligibility, genetic risk factors, and patient response. Generic lenalidomide products continue to improve treatment accessibility while maintaining the same active ingredient as the reference medicine, Revlimid®.
Disclaimer: Lenalid 25 mg (Lenalidomide) is a prescription-only anti-cancer medicine. It should be used only under the supervision of a qualified oncologist or haematologist. Regular monitoring of blood counts, kidney function, and pregnancy prevention measures is essential during treatment.
Dubai's Mediclinic City Hospital, American Hospital Dubai, and Cleveland Clinic Abu Dhabi (serving Dubai patients) manage multiple myeloma for the UAE's most populous emirate — a diverse myeloma population encompassing Emirati nationals (with government-covered Thiqa health insurance), Western expatriates with comprehensive private insurance, and a large South Asian working population with basic to moderate insurance coverage. Lenalid 25mg provides Dubai myeloma patients with affordable Lenalidomide across all insurance tiers at dramatically reduced cost versus UAE private oncology pricing.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: How does Mediclinic City Hospital's oncology programme in Dubai manage myeloma including Lenalid?
Mediclinic City Hospital — Dubai's flagship private hospital located in the Dubai Healthcare City free zone — operates one of the UAE's most comprehensive oncology programmes, drawing internationally trained haematologists and oncologists who manage myeloma to IMWG (International Myeloma Working Group) standards. Mediclinic City's myeloma capability: autologous stem cell transplantation programme — one of the few UAE hospitals performing ASCT, attracting myeloma patients from across the Gulf region; multiple myeloma multidisciplinary team including haematologists, stem cell transplant specialists, clinical pharmacists, and oncology nurses; molecular diagnostic capability including FISH (fluorescence in situ hybridisation) for myeloma cytogenetic risk stratification (del17p, t(4;14), 1q gain); and access to novel agents including Daratumumab, Carfilzomib, and Ixazomib through hospital pharmacy. Lenalid 25mg positioning in Mediclinic City's myeloma protocols: post-ASCT maintenance — Lenalid initiated at Mediclinic City approximately 3-6 months after ASCT when neutrophil and platelet counts have recovered; VRD induction for transplant-eligible newly diagnosed Dubai myeloma patients; DRd for transplant-ineligible patients; and second-line combination regimens for relapsed disease. UAE insurance coverage for Lenalid at Mediclinic City: comprehensive Dubai Health Authority (DHA) essential benefit plans cover oncology medications with pre-authorisation; Western expat plans through Cigna, AXA, and Bupa International typically cover Lenalid at 80-90% with co-insurance applied; Lenalid 25mg from Unnati Pharmax serves Dubai myeloma patients with high co-insurance obligations or coverage gaps in their DHA-mandated plan.FAQ 2: How does Dubai's medical tourism dimension affect myeloma and Lenalid management?
Dubai Health Authority's medical tourism initiative — "Dubai Health Experience" (DHX) — has actively attracted international medical tourists for specialised procedures including autologous stem cell transplantation for myeloma. Dubai's medical tourism myeloma profile: Gulf Cooperation Council (GCC) nationals from Saudi Arabia, Kuwait, Bahrain, Qatar, and Oman frequently travel to Dubai's Mediclinic City or American Hospital for ASCT — facilities that offer equivalent care to Saudi Aramco Hospital or Kuwait cancer centres, often with shorter wait times and the appeal of Dubai's hospitality environment. Post-ASCT Lenalid maintenance for medical tourist myeloma patients: GCC medical tourists who receive ASCT at Mediclinic City Dubai return to their home countries for Lenalid maintenance; their ongoing Lenalid supply is managed through: their home country's oncology team (taking over maintenance prescribing from the Dubai Mediclinic team); or through Mediclinic City's telemedicine follow-up with Lenalid dispensed in Dubai and carried home. Lenalid 25mg from Unnati Pharmax specifically serves Saudi, Kuwaiti, and other GCC myeloma patients who received ASCT in Dubai and are now in their home countries — where Lenalid may be expensive or intermittently available through local channels; DHL delivery from Unnati Pharmax directly to Riyadh, Kuwait City, or Manama provides these post-Dubai-ASCT patients with reliable Lenalid supply at dramatically reduced cost versus Gulf private oncology pricing.FAQ 3: What VTE prophylaxis protocol does Mediclinic City Dubai use for Dubai myeloma patients on Lenalid?
Lenalidomide-associated VTE risk is a critical safety concern for Dubai's myeloma patients — and Mediclinic City's oncology team implements a rigorous Dubai-specific VTE prophylaxis framework. Dubai's VTE risk context: several factors in Dubai's population amplify Lenalid's VTE risk beyond standard Western populations; dehydration — Dubai's heat creates dehydration risk that concentrates clotting factors; immobility — Dubai's car-centric culture and myeloma fatigue create significant immobility; flight travel — Dubai is a major aviation hub, and myeloma patients travel frequently on long-haul flights (Dubai-London-NY routes regularly); pre-existing hypercoagulable conditions — some UAE South Asian community members carry Factor V Leiden or prothrombin gene mutations. Mediclinic City's Lenalid VTE prophylaxis protocol: for Lenalid + low-dose Dexamethasone maintenance (standard post-ASCT Dubai protocol): aspirin 100mg daily for patients without additional VTE risk factors; LMWH (Enoxaparin) for patients with prior VTE, immobility, or planned long-haul travel during Lenalid treatment; Apixaban or Rivaroxaban (DOACs) increasingly preferred for Dubai's higher cardiovascular risk South Asian myeloma patients. Flight travel guidance for Dubai Lenalid patients: long-haul flights create DVT risk from immobility and dehydration — Dubai Lenalid patients on maintenance who travel to India, UK, or US should: wear compression stockings; perform in-flight exercises hourly; maintain excellent hydration; and discuss with Mediclinic City's haematologist whether temporary LMWH is warranted for flights above 8 hours during Lenalid treatment.FAQ 4: How does Dubai's summer (June-September) extreme heat affect Lenalid 25mg storage and adherence?
Dubai's summer — sustained temperatures above 40°C with humidity creating heat index values above 55°C — creates pharmaceutical storage challenges for all medications, but Lenalid's oncology importance makes its storage integrity particularly critical. Lenalid 25mg storage requirements: room temperature 15-30°C, protected from moisture and light; standard air-conditioned Dubai apartment interiors maintain 20-24°C throughout summer — appropriate for Lenalid storage. Storage risks specific to Dubai summer: vehicle storage — Dubai cars reach 60-80°C interior temperatures in summer parking; Lenalid tablets left in glove compartments or bags in parked vehicles during Dubai's June-August peak will experience temperature-related stability degradation; outdoor balcony or terrace storage — direct sun on Dubai's balconies reaches 50-60°C surface temperature; outdoor storage of any medication including Lenalid is completely inappropriate during Dubai's summer. DHL delivery in Dubai summer: packages left outside building entrances, at unmanned courier drop points, or in outdoor common areas in Dubai's summer heat can experience damaging temperature exposure within minutes; Dubai Lenalid patients from Unnati Pharmax should: arrange for DHL delivery to a concierge-managed building or ensure someone is home to receive; use DHL's Dubai delivery tracking to receive packages immediately; and order during the cooler months (November-April) to build a supply buffer that avoids summer delivery requirements. Adherence in Dubai's summer: Ramadan's fasting in recent years has fallen in spring-summer, overlapping with the Lenalid-with-food question — Lenalid has no food requirement, making Ramadan Iftar-timed dosing straightforward for Dubai's Muslim myeloma patients, unlike food-interaction-sensitive medications.FAQ 5: How does the UAE's growing cancer care infrastructure affect long-term Lenalid access for Dubai's myeloma community?
The UAE's healthcare infrastructure investment in oncology is among the Gulf's most ambitious — Dubai Health Authority's Dubai Cancer Strategy 2020-2025 set targets for improved cancer detection, treatment capacity, and patient outcomes that are being implemented through 2026. How Dubai's expanding oncology infrastructure affects Lenalid access long-term: Pharmaceutical access improvement: DHA's essential benefit package requirements for employer health insurance now mandate oncology medication coverage — this expansion has increased the proportion of Dubai myeloma patients with Lenalid-covered insurance; however, coverage depth (co-insurance percentages, annual maximums) varies significantly between plans, and the "covered" medication may still create significant financial burden. New oncology facilities: the 2025 opening of Dubai's expanded Mediclinic City Oncology Centre and the DHA's Sheikh Hamdan bin Rashid Al Maktoum Cancer Centre have increased ASCT capacity in Dubai — more Dubai myeloma patients can receive ASCT locally rather than travelling internationally; post-ASCT Lenalid maintenance at Dubai facilities is growing. Generic medicine access in UAE: DHA's generic medicine promotion initiative — encouraging substitution of brand medications with approved generic equivalents — should theoretically improve Lenalid 25mg accessibility; however, the UAE generic approval pathway is slower than India's WHO-GMP certification system; Indian WHO-GMP certified Lenalid 25mg from Unnati Pharmax continues filling the gap between UAE's brand-dominated oncology pharmacy environment and affordable generic access. Unnati Pharmax's position in Dubai's evolving myeloma landscape: as Dubai's oncology infrastructure matures, Unnati Pharmax's role transitions from primary access to gap-filling — serving the co-insurance burden, supply disruption, and non-insured segments that even a maturing healthcare system leaves incompletely addressed.Website
Email Id
Contact Number
+91-8265041513
Generic-Revlimid-Lenalid-25mg-Dubai
